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Abstract
Background: The Sonic hedgehog (Shh) signaling pathway is critical for cell growth and differentiation.
Impairment of this pathway can result in both birth defects and cancer. Despite its importance in cancer
development, the Shh pathway has not been thoroughly investigated in tumorigenesis of brain tumors. In this
study, we sought to understand the regulatory roles of GLI1, the immediate downstream activator of the Shh
signaling pathway on its downstream target genes PTCH1, Cyclin D2, Plakoglobin, NKX2.2 and PAX6 in
medulloblastoma and astrocytic tumors.
Methods: We silenced GLI1 expression in medulloblastoma and astrocytic cell lines by transfection of siRNA against
GLI1. Subsequently, we performed RT-PCR and quantitative real time RT-PCR (qRT-PCR) to assay the expression of
downstream target genes PTCH1, Cyclin D2, Plakoglobin, NKX2.2 and PAX6. We also attempted to correlate the
pattern of expression of GLI1 and its regulated genes in 14 cell lines and 41 primary medulloblastoma and
astrocytoma tumor samples. We also assessed the methylation status of the Cyclin D2 and PTCH1 promoters in
these 14 cell lines and 58 primary tumor samples.
Results: Silencing expression of GLI1 resulted up-regulation of all target genes in the medulloblastoma cell line,
while only PTCH1 was up-regulated in astrocytoma. We also observed methylation of the cyclin D2 promoter in a
significant number of astrocytoma cell lines (63%) and primary astrocytoma tumor samples (32%), but not at all in
any medulloblastoma samples. PTCH1 promoter methylation was less frequently observed than Cyclin D2 promoter
methylation in astrocytomas, and not at all in medulloblastomas.
Conclusions: Our results demonstrate different regulatory mechanisms of Shh-GLI1 signaling. These differences
vary according to the downstream target gene affected, the origin of the tissue, as well as epigenetic regulation of
some of these genes.
Background
The Sonic hedgehog (Shh) signaling pathway is crucial
for embryonic development and is involved in the fate
of many tissues during organogenesis, including the cen-
tral nervous system [1-4]. Additionally, the Shh signaling
pathway has been implicated in stem cell renewal [5] as
well as in the development of tumors such as medullo-
blastoma [1,6], prostate cancer [2,7,8] colorectal carci-
noma [9], and glioma [10].
This pathway is initiated by ligation of the Shh protein
with its receptor PTCH1 on a target cell. Its binding
relieves the inhibition of Smoothened (SMO) by PTCH1.
The active SMO enters the cytoplasm and activates
GLI1. GLI1 is then phosphorylated by the fused serine/
threonine kinase [11] and Costal-2, a kinase-like cyto-
plasmic protein (Cos2) [12], and finally enters the
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nucleus where it acts as a transcriptional regulator on
the promoter regions of different target genes. Down-
stream target genes of GLI1 are PTCH1, Wnt, as well as
other genes such as Cyclin D2 and Plakoglobin. These
genes have consensus sequences for GLI1 binding in
their 5’upstream promoter region. Reports have shown
that Cyclin D2 is up-regulated while Plakoglobin is
down-regulated by GLI1 in epithelial transformed cell
lines [13].
Direct regulation of PAX6 and NKX2.2 by GLI1 has
not yet been reported. However, Shh signaling regulates
expression of these genes during the early embryonic
stage of neuronal development. PAX6 is down-regulated
and NKX2.2 is up-regulated by Shh in a dose dependent
manner [14]. PAX6 also inhibits glioma invasion and
acts as a tumor suppressor gene [15,16]. NKX2.2 is
expressed in low-grade gliomas but not in high-grade
gliomas [17]. However, direct regulation of these genes
by GLI1 has not been studied in major brain tumors
such as medulloblastomas and astrocytomas.
Reports have shown that medulloblastomas arise from
granule cell progenitors (GCP) \ [18,19] by two postu-
lated mechanisms: either excessive signaling stimulating
GCP proliferation, or absence of appropriate signals for
GCPs to stop dividing [20]. The role of Shh signaling
pathway in medulloblastoma tumor development had its
origins in the Gorlin syndrome, also known as the basal
cell carcinoma syndrome, an autosomal dominant dis-
ease with an incidence of about 1 in 50,000 live births.
Gorlin syndrome is caused by PTCH1 mutations in
about 85% of cases. At least 25% of medulloblastoma
sporadic tumors show PTCH1 mutations [21]. The
major focus of medulloblastoma tumor research is now
based upon GCPs as a source of medulloblastoma,
although certain populations of neural stem cells (NSCs)
are gaining importance [22,23]. The role of Shh signal-
ing is less well studied in astrocytomas. Additionally, the
involvement of GLI1 downstream target genes such as
PTCH1, Cyclin D2, Plakoglobin, NKX2.2 and PAX6 have
not been studied in either tumor.
In our study, we have silenced expression of GLI1
using a small interfering RNA (siRNA), followed by the
determination of gene expression patterns of PTCH1,
Cyclin D2, Plakoglobin, NKX2.2 and PAX6 in 14 cell
lines and 41 primary medulloblastoma and astrocytoma
tumor samples.
Our observations on the expression of GLI1, Cyclin
D2, and PTCH1 in astrocytoma cell lines as well as
tumor samples revealed a significant proportion of sam-
ples showing low or null levels of Cyclin D2 and
PTCH1, even in the presence of high GLI1 expression.
However, high levels of GLI1 correlated with high levels
of Cyclin D2 and PTCH1 in medulloblastoma cell lines
and tumor samples.
We also explored the possibility of epigenetic regula-
tion of Cyclin D2 and PTCH1 in astrocytic cell lines and
samples. We used demethylating agents including
5-Aza-2’-deoxycytidine (5-Aza-2’-dC) and the histone
deacetylase (HDAC) inhibitor Trichostatin A, to assess
reversal of expression of Cyclin D2 in astrocytic cell
lines wherein the gene is not naturally expressed. To
further our understanding of epigenetic regulation, we
also monitored the methylation status of the Cyclin D2
and PTCH1 promoters in 14 cell lines and 58 tumor
samples derived from medulloblastomas and astrocyto-
mas. We performed melting curve analysis-methylation
assays (MCA-Meth) and melting curve analysis-methy-
lated specific PCR (MCA-MSP) to assess methylation at
these genetic loci [24].
Thus, our objectives were two-fold: first, to determine
whether GLI1 up-regulates any of its downstream effec-
tors; and second, to study potential epigenetic regulation
of PTCH1 and Cyclin D2.
Methods
Cell lines
For this study, we chose 6 medulloblastoma cell lines
(TE671, PFSK-1, Daoy, TE671c2, D283Med and SK-PN-
DW) and 8 high-grade astrocytoma cell lines (U87MG,
A172, LN405, SW1783, T98G, SW1088, CCF-STTG1,
and GOS-3). The cell lines PFSK-1, Daoy, D238,
SK-PN-DW, CCF-STTG1, SW1088 and SW1783 were
purchased from the American Type Culture Collection
(Manassas, VA, USA). A172, T98G and U87MG were
purchased from the European Collection of Cell Culture
(Salisbury, Wiltshire, UK). TE671, TE671c2, LN405 and
GOS-3 were obtained from the Deutsche Sammlung
von Mikroorganismen und Zellkulturen (Braunschweig,
Germany). The cell lines were cultured in RPMI L-Glu-
tamax medium (GIBCO-BRL, Gaithersburg, MD, USA),
supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin, 0.1% amphotericin B, and for
medulloblastoma cell lines, 10% non-essential amino
acids (NEAs). Cells lines were maintained at 37°C in the
presence of 5% CO2. On attaining 80% confluence, the
cells were split using trypsin/EDTA (1×) and plated in
new sterile flasks.
Primary tumor samples
We used 14 primary medulloblastomas (Tables 1 and 2)
and 44 primary astrocytomas (Tables 3 and 4). The use
of medulloblastoma samples for research purposes was
approved by Johns Hopkins Medical Institute (JHMI),
USA Institutional Review Board under protocol #99-12-
29-05. Similarly, the use of astrocytoma samples was
approved by the Ethical Committee of the University of
Navarra Medical School, Pamplona, Spain under the
protocol #38/2002, February and 04/2/2008.
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The astrocytomas were of WHO grades I to IV. All
samples were snap frozen immediately on resection and
stored at -80°C. Genomic DNA, RNA and proteins were
extracted from the frozen tissues.
GLI1 siRNA transfection and knock-down
For these experiments, we selected the medulloblastoma
cell line Daoy, and the astrocytic cell line U87MG,
which were grown in RPMI L-Glutamax medium
(GIBCO-BRL, Gaithersburg, MD, USA), supplemented
with 2% fetal bovine serum (FBS) at 37°C in the
presence of 5% CO2. We procured siRNA against the
GLI1 gene from Stealth™ (Invitrogen, USA) GLI1
RNAi: GCACAUACCUGCUUCGGGCAAGAUAU
(GLI-HSS104170) and AUAUCUUGCCCGAAGCAG-
GUAGUGC (GLI-HSS104170), along with a universal
negative siRNA to control for non-specific interference
by the siRNA. The universal negative siRNA used was a
scrambled sequence with medium GC content and does
not influence expression of the target gene. The GLI1
siRNA and the scrambled siRNA were delivered to the
Daoy and U87MG cell lines (100 nM/well), using
Lipofectamine™ 2000 as the transfection reagent and
Opti-MEM® I reduced serum media as a mixing reagent
solution for the siRNA and LipofectamineTM 2000. We
used BLOCK-iT™ Fluorescent Oligo tagged with fluores-
cein to assess and optimize cationic lipid-mediated
delivery of siRNA into the Daoy and U87MG cell lines.
Following efficient transfection, we extracted RNA from
cells transfected with GLI1 siRNA, scrambled siRNA, as
well as untransfected cells after 72 h. Finally, we
assessed efficiency of GLI1 silencing in the two cell
lines. The extracted RNA was used to assess expression
levels of downstream target genes of the Shh pathway
such as PTCH1, Cyclin D2, Plakoglobin, PAX6 and
NKX2.2.
Table 1 Promoter methylation and expression correlation of Cyclin D2 and PTCH1 gene in medulloblastoma cell lines
Cell
lines
Cyclin D2
expression
Cyclin D2
promoter
hypermethylation
by MCA-Meth
Cyclin D2
Hypermethylation
by MSP
Cyclin D2
Hypermethylation
by both methods
No Hyper
Methylation in
Cyclin D2
Promoter
PTCH1 Expression
in
medulloblastoma
cell lines
PTCH1 promoter
Hypermethylation
by MCA-MSP
method
TE671 ++ U M ++ U
PFSK-1 ++ M M √ ++ U
Daoy ++ U U+M ++ U
TE671c2 ++ U U+M + U
D283 ++ U U + M + U+M
SK-PN-
DW
+ U+M M √ + U
-: no expression; +: expression; ++: high expression; √: yes
Table 2 Promoter methylation and expression correlation of Cyclin D2 and PTCH1 gene in medulloblastoma samples
MB
samples
ID
Patients’
Date of
Birth (D/M/
Y)
Sex Expression of
Cyclin D2 in
primary tumor
samples
Promoter
methylation by
MCA-Meth in
Cyclin D2
Promoter
methylation
by MSP in
Cyclin D2
No Promoter
hypermethylation
in Cyclin D2
Expression of
PTCH1 in
primary tumor
samples
Promoter
hypermethylation
in PTCH1 by MCA-
Meth of PTCH1
p3 5/18/1969 M ++ U U √ - U + M
p4 3/9/1987 M - U U + M + U
p7 11/27/1987 M ++ U U √ + U
p10 4/15/1971 M ++ U U √ nd U
p11 4/30/1997 F + U U + M - U + M
p13 8/21/1995 F + U U + M nd U
p14 9/9/1991 F ++ U U √ + U
p17 11/30/1988 M ++ U U √ + U
p20 11/22/1978 M ++ U U √ + U
p21 11/15/1987 M ++ U U √ + U
p29 3/9/1974 M ++ U U √ nd U
p30 6/24/1991 M ++ U U √ nd nd
p23 8/15/1984 F nd nd nd nd nd nd
p52 10/5/1991 M nd nd nd nd nd nd
MB: medulloblastoma; -: no expression; +: expression; ++: high expression; √: yes
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Table 3 Cyclin D2 and PTCH1 expression and promoter hypermethylation analysis in astrocytic cell lines
Astrocytic
Cell lines
Cyclin D2
expression
Cyclin D2
Expression after
5’aza+TSA
Cyclin D2 promoter
hypermethylation analysis
by MCA-MSP
Cyclin D2 promoter
hypermethylation Analysis
by MCA-Meth
Cyclin D2
Hypermethylation by
both techniques
No
Hypermethylation
in Cyclin D2
promoter
PTCH1
expression in
glioma cell lines
PTCH1 promoter
hypermethylation by
MCA-MSP
U87MG + + √ √ √ +/-
A172 - + √ -
LN405 + + √ +
SW1783 - + √ -
T98G - ++ √ √ √ ++
SW1088 + + √ ++
CCF-STTG-1 - + √ ++ √
GOS-3 - ++ √ √ √ ++
-: no expression; +: expression; ++: high expression; √: yes
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Table 4 Expression and promoter hypermethylation analysis of Cyclin D2 and PTCH1 gene in astrocytic tumor samples
Astrocytic
tumor samples
Grade and
Sample ID
Expression of
Cyclin D2 in
tumor
samples
Methylation
by MSP in
Cyclin D2
promoter
Methylation by
MCA-Meth in
Cyclin D2
promoter
Methylation by
both techniques
in Cyclin D2
promoter
No
hypermethylation
in Cyclin D2
promoter
Expression
of PTCH1 in
tumor
samples
Methylation of
PTCH1
promoter by
MCA-Meth
GBM(3) - √ √ √ - √
AIII(4) ++ √ +
GBM(5) - √ +/-
GBM(6) - √ +/-
AIII(7) + √ +/-
GBM(8) - √ ++
GBM(9) + √ -
AIII(10) - √ +/-
GBM(11) ++ √ +/-
GBM(12) + √ +
GBM(13) - √ √ √ + √
AIII(14) ++ √ -
GBM(15) - √ +/-
AIII(16) ++ √ +/-
GBM(17) - √ ++
GBM(18) - √ √ √ +
AIII(19) + √ +
AII(20) + √ +
AIII(21) - √ - √
GBM(22) - √ -
GBM(23) - √ +
GBM(24) - √ √ √ +
AI(25) ND √ ND
GBM(26) ND √ ND
GBM(27) ND √ ND
GBM(28) ND √ ND
GBM(29) ND √ ND
GBM(30) + √ +
GBM(31) ND √ ND
GBM(32) ND √ ND
AI(34) ND √ ND
AIII(35) ND √ ND
GBM(36) ND √ ND
GBM(41) ND √ ND
GBM(43) + √ -
GBM(44) ND √ ND
GBM(45) ND √ ND
GBM(46) ND √ ND
GBM(47) ND √ ND
GBM(48) ND √ ND
GBM(49) ND √ ND
AII(50) ++ √ -
GBM(51) - √ -
GBM(52) ++ √ +
-:no expression; +/-: low expression; +: expression; ++: high expression; √: yes; nd: not determined
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Standard RT-PCR and quantitative real time RT-PCR (qRT-
PCR)
We used the QuickPrep Total RNA extraction Kit
(Amersham Biosciences, UK) to extract RNA from the
two transfected cell lines, Daoy and U87MG. Normal
adult brain RNA (Stratagene, Cedar Creek, TX) was
used as a control for mRNA expression. A total of 1 μg
of RNA was converted to cDNA by the Superscript II
RNase H Reverse Transcriptase kit (Invitrogen, Life
Technologies, Carlsbad, CA). The cDNA was amplified
by standard RT-PCR using oligonucleotides published
elsewhere [9]. We compared mRNA expression in GLI1
silenced cell lines with cells transfected with scrambled
siRNA as well as untransfected cell lines. We confirmed
GLI1 silencing by quantifying GLI1 transcript expression
in the silenced samples by qRT-PCR, and compared
these levels with samples transfected with scrambled
siRNA and untransfected cell lines. We also determined
expression levels of Cyclin D2, Plakoglobin, NKX2.2 and
PAX6 by qRT-PCR in silenced, control, and untrans-
fected cell lines. Thereafter, we assessed the expression
of these genes in 14 medulloblastoma and astrocytoma
cell lines as well as 41 primary tumor samples by qRT-
PCR. Transcript expression of every gene was normal-
ized to GAPDH [25]. For qRT-PCR we used iQ™ SYBR®
Green Supermix (Bio-Rad, Hercules, CA) as the fluores-
cence dye to monitor amplification of cDNA. Each sam-
ple was run in triplicate and the means and standard
deviations were determined. We also compared expres-
sion of the candidate genes in our samples with expres-
sion in normal human brain tissue. Reaction conditions
for qRT-PCR were 95°C for 10 min, followed by 35
cycles of 95°C (denaturation) for 1 min, 57.4°C to 62°C
(annealing temperature, depending on the gene ampli-
fied) for 1 min, and 72°C (extension) for 50 s. Further,
melting curve analysis was carried out at 72°C for 1
min, and 95°C for 10 mins.
Western blotting
Proteins were extracted from 8 astrocytoma cell lines
and 12 primary astrocytic tumor samples (randomly
selected) using the RIPA buffer (0.5% sodium deoxyco-
late, 0.1% SDS, 1% NP40, in 1× PBS supplemented with
protease inhibitor cocktail and PMSF). We were unable
to extract protein from medulloblastoma samples due to
shortage of tumor samples. A total of 20-30 μg of pro-
tein per sample was loaded on a gel for western blotting.
The resolved proteins were transferred onto a nitrocel-
lulose membrane (Bio-Rad, Hercules, CA, USA). The
membrane was blocked with 5% non-fat milk in TBST
buffer to prevent nonspecific binding. The membrane
was exposed to the primary antibody: anti-GLI1 (goat
polyclonal (N-19); Santa Crux, CA, USA) and anti-
Cyclin D2 (rabbit polyclonal (H-289) Santa Cruz, CA,
USA) antibodies at 1:400 and 1:200 dilution, respectively
in 5% skim milk in TBST overnight at 4°C. The mem-
branes were subsequently exposed to HRP-conjugated
secondary antibodies (antigoat IgG and anti-rabbit IgG
at a dilution of 1:5000 in TBST) and incubated for 1-2 h
at room temperature. Positive interaction of the antibo-
dies with the target protein was detected by enhanced
chemiluminescence (ECLTM Western Blotting Analysis
System, Amersham Biosciences, Piscataway, NJ, USA)
and autoradiography.
Epigenetic studies of Cyclin D2 and PTCH1 promoters
Treatment of cells with 5-aza-2’-deoxycytidine and TSA
were undertaken according to our previous protocol
[26]. Bisulfite modification of genomic DNA extracted
from the cell lines and tumor samples was performed
using the CpGenome DNA modification Kit S7820
(Chemicon International).
Cyclin D2 promoter methylation analysis
We identified three putative CpG-rich promoter regions
[27]. The first CpG island ranges from -1550 to -1288
upstream of the start site (262 bp), the second from
-1230 to -982 (248 bp), and the third from -296 to -104
(192 bp). These three regions contain consensus binding
sequences for several transcription factors including
AP2, PUF, STF, PEA3, E2F and PEA3 [27]. The consen-
sus sequence (GCTCTGCTCGCCCACCACC-
CAATCCTCGCCTC) for binding of GLI1 onto the
Cyclin D2 promoter region is present in the third CpG
island.
We analyzed the Cyclin D2 promoter by two indepen-
dent methods. The first was MCA-Meth [24] (a 108 bp
product was amplified from the first CpG region: from
-1462 to -1354). The second method was MSP-PCR
(primer pairs for this method were taken from a pre-
viously published article [28]). Unmethylated primers
amplified the region from -1616 to -1394 (first CpG
-rich region) giving a product of 222 bp; methylated pri-
mers amplified the region from -1394 to -1152 (covering
the first and second CpG rich regions) producing a pro-
duct of 276 bp.
PTCH1 promoter methylation analysis
We analyzed the promoter region of PTCH1 from -238
to +62 bp [29], which corresponds with exon 1B [30].
To assess methylation of the PTCH1 promoter, we fol-
lowed the MCA-MSP method [24]. This method gives
us two melting peaks which are dependent on amplifica-
tion with unmethylated or methylated primers.
Statistical analysis
Statistical analyses were performed using Graphpad
Prism 4 (Graphpad Software Inc., San Diego, CA). Data
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graphed with error bars represent mean and SD from
experiments performed in triplicate, unless otherwise
noted. Fisher’s exact test was used to determine the sig-
nificance of any difference.
Results
Expression of GLI1 target genes after siRNA-mediated
GLI1 silencing
We transfected Daoy and U87MG cell lines with GLI1
siRNA and scrambled siRNA. We monitored the effi-
ciency of transfection using lipofectamine through the
delivery of the BLOCK-iT™ Fluorescent Oligo (Figures
1A-F). Images were captured using a fluorescent ima-
ging microscope and similar efficiencies of transfection
were attained for both the GLI1 siRNA and the
scrambled siRNA. To assess efficiency of silencing,
expression of GLI1 was monitored by RT-PCR after
transfection. Approximately 86% and 40-4 5% silencing
of GLI1 transcript was achieved in Daoy and U87MG
cell lines respectively (Figures 2A-B).
Silencing of GLI1 resulted in a 50% and 60% decrease
in PTCH1 expression in Daoy and U87MG cell lines
respectively (Figures 2C-D). In contrast, Cyclin D2
showed a 17% decrease in Daoy and 113% increase in
U87MG cells (Figures 2E-F). Plakoglobin expression was
decreased by 30% in Daoy cells and increased by 125%
in U87MG cells (Figures 2G-H). PAX6 expression was
decreased by 35% in Daoy cells and increased by 100%
in U87MG cells (Figures 2I-J), and NKX2.2 was
decreased by 50% in Daoy cells and unaltered in
U87MG cells (Figures 2K-L). All changes listed were
specific to GLI1 silenced cells and cells transfected with
scrambled siRNA or untransfected cells did not show
similar trends.
PTCH1
siRNA-mediated silencing of GLI1 resulted in an 86%
decrease in GLI1 transcript and a 50% decrease in
PTCH1 transcript in the Daoy cell line compared with
scrambled siRNA and untransfected Daoy cell lines.
We subsequently sought to determine the pattern of
PTCH1 transcript expression in 6 medulloblastoma cell
lines and 14 primary medulloblastoma samples and
observed that 50% of the cell lines and tumor samples
showed high expression of PTCH1 [26] (Figure 3A).
However, we were unable to find any significant correla-
tion between GLI1 and PTCH1 expression in the cell
lines and tumor samples (p = 0.07).
We also analyzed 27 astrocytoma tumor samples for
co-expression of PTCH1 and GLI1. We observed a
mixed expression pattern amongst the low-grade to
high-grade samples. Few of the high-grade tumors
expressed high levels of PTCH1 in the absence of GLI1
expression and few of them showed high expression in
the presence of GLI1 expression. Overall, the pattern of
PTCH1 expression was low amongst all samples, despite
varying levels of GLI1 expression (Figure 3B).
Cyclin D2
Silencing GLI1 in the Daoy cell line resulted in a 17%
decrease in Cyclin D2 expression compared with
scrambled siRNA and untransfected cell lines (Figure
2E). We evaluated Cyclin D2 expression in 6 cell lines
and 14 medulloblastoma tumor samples and observed
that most of them showed high expression levels of
Cyclin D2, with the exception of cell line SK-PN-DW
(Figure 4A) and one tumor sample (Figure 3C, Table 2).
We did not observe any significant correlation between
GLI1 and Cyclin D2 expression.
Six astrocytoma cell lines (U87MG, A172, LN405,
SW1783, T98G and SW1783) expressed Cyclin D2 at
very low levels, and two cell lines (CCF-STTG-1 and
GOS-3) did not express Cyclin D2 compared to normal
adult brain tissue (p = 0.006) (Figure 4B). Fourteen high
grade astrocytomas (grades III and IV) were assessed for
Cyclin D2 and GLI1 expression: only 2 glioblastomas
(grade IV) co-expressed Cyclin D2 and GLI1 at high
levels (Figure 3D). Low levels of GLI1 were found to be
associated with high expression levels of Cyclin D2 in
the glioblastoma samples (p = 0.007).
Plakoglobin
We observed a 30% decrease in expression of Plakoglo-
bin in upon silencing of GLI1 in Daoy transfected cells
(Figure 2G). Most of the 6 cell lines and 14 primary
tumor samples analyzed showed high expression levels
of Plakoglobin compared to normal brain tissue (Figure
4C). Additionally, we detected an inverse correlation in
levels of expression of GLI1 and Plakoglobin in primary
medulloblastoma samples, with the exception of two
tumors (Figure 3E). However, this correlation was not
significant.
Among the 8 astrocytic cell lines, 5 (U87MG, A172,
LN405, SW1783 and T98G) showed low levels of Plako-
globin expression, and the remaining 3 (SW1088, CCF-
STTG-1 and GOS3) expressed Plakoglobin at levels
higher than seen in normal adult brain tissue (p = 0.02)
(Figure 4D). A majority of the astrocytic tumor samples
(24/27, 89%) expressed Plakoglobin at low levels com-
pared to normal brain tissue (Figure 3F). There was a
distinct pattern of Plakoglobin expression in astrocytic
tumor samples: low-grade (AII) samples did not express
Plakoglobin and few high-grade samples highly
expressed Plakoglobin in the absence of GLI1 mRNA
expression. The remaining samples expressed Plakoglo-
bin at low levels in the presence of GLI1.
PAX6
Our results show a 35% reduction in expression of
PAX6 gene upon GLI1 silencing in the Daoy cell line
compared with scrambled and untransfected controls
(Figure 2I). In our study, we monitored the expression
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of the PAX6 gene in 6 medulloblastoma cell lines and
14 medulloblastoma primary tumor samples: a majority
of the cell lines showed moderate expression levels of
PAX6 with the exception of the PFSK-1 and D283 cell
lines (p = 0.015) (Figure 4E). Similarly, most of the
primary tumor samples showed high levels of PAX6
expression compared to GLI1 in the same samples
(Figure 3G).
Most of the astrocytic cell lines (A172, SW1783,
T98G, SW1088, CCF-STTG-1 and GOS-3) expressed
PAX6 at low levels, and only 2 (U87MG and LN405)
expressed PAX6 at high levels compared to normal
adult brain tissues (p = 0.006) (Figure 4F). Amongst the
primary tumor samples, 20/27 (74%) samples showed
low expression of PAX6 as compared to normal adult
brain tissue (Figure 3H). Interestingly, most of the astro-
cytic tumor samples showed low expression levels of
PAX6 even though GLI1 was expressed at high levels.
NKX2.2
Silencing of GLI1 resulted in a decrease in NKX2.2 by
50% in the Daoy cell line compared with scrambled
siRNA transfected and untransfected cells (Figure 2K).
Expression of NKX2.2 was low in 2 cell lines (Daoy and
TE671c2), high in only one (SK-PN-DW) (p = 0.015)
and was not expressed in the remaining 3 (TE671,
PFSK-1 and D283) (Figure 4G). Primary medulloblasto-
mas also showed a similar pattern of low expression of
NKX2.2 and this correlated with high expression levels
of PAX6 (Figures 3G-I).
Six astrocytic cell lines (A172, LN405, T98G, SW1088,
CCF-STTG-1 and GOS-3) showed very low expression
of NKX2.2, and the remaining 2 cell lines (U87MG and
SW178) did not express it at all, compared with expres-
sion levels in normal adult brain tissue (p = 0.0001)
(Figure 4H). Out of the 27 astrocytic tumor samples, 20
(74%) showed low expression of NKX2.2 compared with
normal adult brain tissue (p < 0.001) (Figure 3J).
Amongst the samples, low-grade tumors did not express
NKX2.2; however, few of the high-grade samples showed
very high expression levels of NKX2.2 and low expres-
sion of GLI1. Overall, most samples expressed NKX2.2
at low levels while expressing GLI1 to a high degree
(Figure 3J).
No correlation between GLI1 and Cyclin D2 protein
expression
GLI1 protein was expressed in most astrocytic cell lines
with the exception of two (U87MG and A172) (Figure
5A). However, very low expression of Cyclin D2 protein
was observed in the following seven cell lines: U87MG,
Figure 1 Transfection of Daoy medulloblastoma cell line and U87MG astrocytoma cell line with GLI1 siRNA. Figure 1A: Daoy cell line is
transfected with Stealth GLI1 siRNA (Invitrogen) with 100 pmol concentration, using Lipofectamine™ 2000 as a transfecting agent and
fluorescein-labeled oligo (BLOCK-iT™ Fluorescent oligo) for identification of trasfection efficency. Figure 1B: Daoy cell line transfected with
universal negative (U neg) siRNA. Figure 1C: Untransfected Daoy cell line. Figure 1D: U87MG cell line is transfected with Stealth GLI1 siRNA
(Invitogen) with 100 pmol concentration, using Lipofectamine™ 2000 as a transfecting agent and fluorescein-labeled oligo (BLOCK-iT™
Fluorescent oligo) for identification of trasfection efficency. Figure 1E: U87MG cell line transfected with universal negative (U neg) siRNA. Figure
1F: Untransfected U87MG cell line.
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Figure 2 qRT-PCR comparative expression of GLI1, PTCH1, Cyclin D2, Plakoglobin, PAX6 and NKX2.2 genes in GLI1 knock-down,
negative and untransfected Daoy medulloblastoma cell line and U87MG astrocytoma cell line. After 72 h of siRNA-mediated transfection,
GLI1 showed 83% decrease in expression in Daoy cell line (Figure 2A) and 40-45% decrease in expression in U87MG cell line (Figure 2B)
compared to universal negative siRNA and untransfected cell lines. The siRNA-mediated GLI1 knock-down cell lines Daoy and U87MG showed
50% (Figure 2C) and 60% (Figure 2D) decrease in expression of PTCH1 respectively. The GLI1 knock-down cell lines (Daoy and U87MG) showed
17% decrease (Figure 2E) and 113% increase (Figure 2F) in expression of Cyclin D2 respectively. The cell lines Daoy and U87MG showed 30%
decrease (Figure 2G) and 125% increase (Figure 2H) in expression of Plakoglobin respectively, compared to universal negative siRNA and
untransfected cell lines. The knock-down cell lines (Daoy and U87MG) showed 35% decrease (Figure 2I) and 100% increase (Figure 2J) in
expression of PAX6 respectively, compared to universal negative and untransfected cell lines. We further checked the expression of NKX2.2 in
these two GLI1 knock-down cell lines (Daoy and U87MG) and found 50% decrease (Figure 2K) and not any changes in the expression of NKX2.2
(Figure 2L) respectively, compared to universal negative and untransfected cell lines.
Shahi et al. BMC Cancer 2010, 10:614
http://www.biomedcentral.com/1471-2407/10/614
Page 9 of 20
Figure 3 qRT-PCR comparative expression of GLI1, PTCH1, Cyclin D2, Plakoglobin, PAX6 and NKX2.2 in medulloblastoma and astrocytic
primary tumor samples. Figure 3A: Most of the medulloblastoma primary tumor samples show high fold GLI1 transcript expression, but PTCH1
expression does not associate. Figure 3B: Most of the astrocytic primary tumor samples showed high fold GLI1 transcript expression but PTCH1
expression is low in most of the primary samples. Figure 3C: Most of the medulloblastoma samples show high expression of GLI1 and Cyclin D2.
Figure 3D: No distinct pattern of Cyclin D2 expression in GBM samples. However, grade III astrocytoma samples show low expression in the
presence of high GLI1 expression. Figure 3E: In case of Plakoglobin there is a reverse relationship in expression of GLI1 in medulloblastoma
except samples 10 and 21. Figure 3F: Low-grade astrocytoma samples do not show Plakoglobin expression, and high-grade astrocytoma
samples show Plakoglobin expression in the absence of GLI1 expression. Figure 3G: Reverse correlation between GLI1 and PAX6 transcript
expression among medulloblastoma samples. Figure 3H: In the presence of high GLI1, there is low expression of PAX6 among astrocytic
samples. Figure 3I: There is not any expression of NKX2.2 among medulloblastoma tumor samples. Figure 3J: Most of the astrocytic tumor
samples show low/absence of expression of NKX2.2 in the presence of GLI1.
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Figure 4 qRT-PCR comparative expression of Cyclin D2, Plakoglobin, PAX6 and NKX2.2 in medulloblastoma and astrocytoma cell lines
(for GLI1 and PTCH1, please check reference [26]). Figure 4A: All 6 medulloblastoma cell lines show equal expression of Cyclin D2 as
compared to normal adult brain tissue; interestingly normal brain itself shows high expression of Cyclin D2. Figure 4B: Four astrocytic cell lines
show very low expression and the remaining 4 cell lines show no expression of Cyclin D2 transcript as compared to normal adult brain tissue (p
< 0.001). Figure 4C: All 6 medulloblastoma cell lines show high fold expression of Plakoglobin compared to normal adult brain tissue. Figure
4D: Five astrocytic cell lines show low expression of Plakoglobin transcript compared to normal brain tissue. Figure 4E: Only one
medulloblastoma cell line, TE671c2, shows high expression fold of PAX6 as compared to normal adult brain tissue. Figure 4F: Most of the
astrocytoma cell lines, except U87MG and LN405, show low expression of PAX6 transcript compared to normal brain tissue. Figure 4G: Most of
the medulloblastoma cell lines show no/low expression of NKX2.2 except SK-PN-DW, as compared to normal adult brain tissue. Figure 4H: All 8
astrocytic cell lines show no/low expression of NKX2.2 transcript compared to normal brain tissue. SYBER Green dye was used for the
quantification of cDNA by qRT-PCR. Comparative expression of samples was plotted on Y-axis with Log10.
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A172, LN405, SW1088, T98G, CCF-STTG-1 and GOS-
3; moreover, there was no expression of Cyclin D2 in
one cell line (SW1783) (Figure 5D). Most of the primary
tumor samples showed high expression levels of the
GLI1 protein (Figures 5B-C) but these samples did not
express Cyclin D2 (Figures 5E-F).
Cyclin D2 and PTCH1 epigenetics
We did not observe any changes in the pattern of Cyclin
D2 expression upon treatment of the medulloblastoma
cell lines with 5-Aza-2’-deoxycytidine and TSA. How-
ever, treatment with these compounds resulted in the
onset of Cyclin D2 expression, assessed by both RT-PCR
and qRT-PCR in five astrocytoma cell lines that did not
initially express Cyclin D2 (A172, SW1783, T98G, CCF-
STTG-1 and GOS-3) (Figures 6A-B) (Table 3).
The increase in Cyclin D2 mRNA in these cell lines
was statistically significant (p = 0.0014) (Figure 6C).
Amongst the 6 medulloblastoma cell lines assayed
using the MCA-Meth method, only PFSK-1 and SK-PN-
DW showed a hemi-methylation melting curve (Figure
7B). However, hypermethylation was revealed in all cell
lines by MSP (Figure 7E) (Table 1). Methylation asso-
ciated with low Cyclin D2 expression was evident only
in the SK-PN-DW cell line (Table 1). In medulloblas-
toma samples, no methylation was detected by MCA-
Meth primers (Figure 7A), even though some tumors
expressed Cyclin D2 at low levels. However, MSP
showed promoter hypermethylation which was asso-
ciated with the lack of mRNA expression or low expres-
sion in tumor samples (Figure 7G) (Table 2).
In astrocytomas, methylation analysis by MCA-Meth
and MSP-PCR methods was performed on 8 cell lines.
Five of the cell lines did not express Cyclin D2, and 3 of
these (U87MG, T98G, and GOS-3) showed methylation/
partial methylation by MCA-Meth analysis (Figures 7B-
C). However, the remaining 2 cell lines did not express
Cyclin D2, nor did they show any methylation curves by
the MCA-Meth method (Figure 7A). However, MSP
identified methylation/partial methylation in 6/8 cell
lines (Figure 7F). U87MG, which showed partial methy-
lation also expressed Cyclin D2, albeit at lower levels
compared with normal adult brain tissue (Table 3). We
performed the same assays to evaluate Cyclin D2 pro-
moter methylation in primary astrocytoma samples and
found that the Cyclin D2 promoter was methylated/par-
tially methylated in 14/44 (32%) of the tumors (Figures
7B-D) (Table 4). MSP-PCR identified 12/44 (27%) of the
samples as methylated at the Cyclin D2 promoter
(Figure 7H). However, only 4 astrocytic tumor samples
(3, 13, 18 and 24) demonstrated Cyclin D2 promoter
hypermethylation by both methods (Table 4).
We also compared the melting curves (using the
MCA-Meth method) of the Cyclin D2 promoter region
before and after treatment with 5-Aza-2’-dexoycytidine
and TSA and found a shift in the melting curve from
the methylated promoter (81°C) to the unmethylated
promoter (78°C) (Figures 8C-D).
Our PTCH1 methylation results among the 6 medul-
loblastoma cell lines identified a methylated peak in
only one cell line, D283 (Figure 8A) (Table 1). This was
associated with low levels of PTCH1 expression. Despite
low expression, we were unable to observe methylated/
unmethylated peaks in 2 other cell lines (TE671c2 and
SK-PN-DW) (Figure 8B). Among medulloblastomas, 2/8
tumor samples showed methylated melting peaks, which
were associated with low expression (Table 2). The
PTCH1 promoter region was methylated as assayed by
the MCA-MSP method in only 1/8 astrocytic cell lines
(CCF-STTG-1 (Figure 8A) and 3/44 (7%) primary tumor
samples. Interestingly, the cell lines and samples show-
ing PTCH1 promoter methylation were either glioblasto-
mas (grade IV astrocytoma) or anaplastic astrocytomas
(AIII) (Tables 3 and 4).
Discussion
In the course of our studies, we sought to understand
the regulation of certain downstream target genes of the
Shh pathway, including PTCH1, Cyclin D2, Plakoglobin,
NKX2.2, and PAX6, in a panel of medulloblastoma and
astrocytoma cell lines and tumors. We attempted to
explore any putative regulation of these genes by the
major transcription factor involved in Shh signaling,
GLI1, as well as at the epigenetic level.
PTCH1
After siRNA-mediated GLI1 silencing in Daoy and
U87MG cell lines, expression of PTCH1 decreased,
compared with scrambled siRNA-transfected and
untransfected cell lines, which may suggest positive reg-
ulation of PTCH1 by GLI1 in medulloblastomas and
astrocytomas. We further assessed PTCH1 expression in
cell lines and samples of both tumor types, and observed
that 50% of the samples showed high expression levels
of PTCH1. This “mixed-pattern” of PTCH1 expression
amongst samples suggests that there may be GLI1 inde-
pendent regulatory mechanisms, both at the genetic
and/or epigenetic level, influencing PTCH1 expression.
It is important to note that reports have shown PTCH1
promoter hypermethylation in several cancers, including
medulloblastomas [31,32].
Our previous study demonstrated a correlation
between high expression levels of GLI1 and PTCH1
[26]. However, some of the cell lines and samples
expressed low levels of PTCH1 in spite of high GLI1
levels, which may be suggestive of the fact that those
cells are in a different phase of GLI1/PTCH1 interplay.
As a putative explanation, high expression of GLI1
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Figure 5 Protein expression of GLI1 and Cyclin D2 in astrocytic cell lines and tumor samples. Figure 5A: The first two cell lines (G1:
U87MG and G2: A172) do not show very distinct bands, but the remaining 6 cell lines (G3: LN405, G4: SW1783, G5: T98G, G6: SW1088, G7: CCF-
STTG-1 and G8: GOS-3) show distinct bands of GLI1 protein. Figures 5B and Figure 5C show GLI1 protein expression in astrocytic tumor
samples 3-8 and 9, 10, 11, 20, 21 and 22. Figure 5D: Low protein expression of Cyclin D2 in astrocytic cell lines G1: U87MG, G2: A172, G3: LN405,
G5: T98G, G6: SW1088, G7: CCF-STTG-1 and G8: GOS-3. Only one cell line (G4: SW1783) does not express Cyclin D2 protein. Figures 5E and
Figure 5F: Cyclin D2 protein expression is not shown in astrocytic tumor samples (3-8 and 9, 10, 11, 20, 21 and 22).
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Figure 6 Reversal of Cyclin D2 expression after treatment with demethylating agent 5-Aza-2’-deoxycytidine and TSA. Figure 6A: All 5
cell lines (A172, SW1783, T98G, CCF and GOS-3) show reversal in the expression of Cyclin D2 by RT-PCR. -: before treatment; +: after treatment.
Figure 6B: Reversal of expression of Cyclin D2 transcript in the 5 cell lines after the treatment with 5-Aza-2’-dC and TSA, by qRT-PCR. Figure 6C:
Comparative fold expression of Cyclin D2 after the treatment with 5-Aza-2’-dC and TSA. Some astrocytic cell lines even showed 200 fold increase
in Cyclin D2 expression (p = 0.0014).
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Figure 7 Promoter methylation analysis of Cyclin D2. 7A-D: Medulloblastoma and astrocytoma cell lines unmethylation melting curve
pattern (Figure 7A); hemi-methylation curve pattern (Figure 7B); partial methylation curve pattern (Figure 7C); and complete methylation
curve (Figure 7D) of Cyclin D2 promoter shown by the MCA-Meth method. Figure 7E: Cyclin D2 promoter methylation in medulloblastoma cell
lines by MSP. Three cell lines (Daoy, TE671c2 and D283) show hemimethylation (U+M) and the remaining three cell lines (TE671, PFSK-1 and SK-
PN-DW) show complete methylation (M). Unmethylated and methylated PCR product bands are 222 and 276 bp, respectively. Figure 7F: Among
astrocytic cell lines three of them (U87MG, SW1783 and GOS-3) show hemi-methylation; 2 show complete methylation (M) (T98G and CCF-STTG-
1); and the other 2 (A172 and LN405) show no methylation (U). Figure 7G: Promoter methylation analysis of medulloblastoma samples. Figure
7H: Promoter methylation analysis of astrocytoma samples.
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associated with low expression of PTCH1 may indicate a
switch-on of Shh signaling (phase 1), trying to exit from
a previous resting point -phase 0- (GLI1 low expression/
PTCH1 low expression), to advance towards phase 2, a
GLI1 high expression/PTCH1 high expression phase
characterized by PTCH1 demethylation and expression,
to finally reach phase 3 (GLI1 low expression/PTCH1
high expression), equivalent to switching off the Shh sig-
naling process.
For epigenetic studies, we chose the distal region 1C
of the PTCH1 promoter [29], and found only 1/6 of the
medulloblastoma cell lines bearing methylation at the
promoter, although two other cell lines also showed low
expression levels of PTCH1. Among the medulloblas-
toma samples, 2/8 (25%) showed methylation together
with lack of PTCH1expression. Several reports have illu-
minated aspects of PTCH1 epigenetic regulation: no
methylation has been reported in the proximal promoter
region 1B of the PTCH1 promoter in primary medullo-
blastomas, suggesting the possibility of methylation of
its distal region, 1C [31]; a knockout mouse tumor
model has documented changes in PTCH1 expression
after treatment with demethylating agents [32]. To fol-
low up on these reports, we decided to further analyze
the hypermethylation of PTCH1 proximal promoter
region, 1B. Our results identified methylation of the pro-
moter region in only 1/8 astrocytoma cell lines and 3/27
(11%) astrocytic tumor samples of high histologic
grades.
The PTCH1 promoter was hypermethylated in mice
tumor models as demonstrated by changes in PTCH1
expression after treatment with demethylating agents
[32]. However, another study suggests that there is no
methylation of the proximal region of the PTCH1 pro-
moter, PTCH1-1B, although methylation may be con-
centrated at the distal end of the promoter, or even
Figure 8 PTCH1 promoter methylation analysis. Figure 8A: PTCH1 promoter methylation curve by MCA-MSP. Figure 8B: PTCH1 promoter
unmethylation curve. Melting curve shown by MCA-Meth. Figure 8C-D. Reversal of methylation melting curve after the treatment with 5-Aza-2’-
dC and TSA in CCF-STTG-1 (Figure 8C) and GOS-3 (Figure 8D) astrocytic cell lines.
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alternative exon variants, including PTCH1-1B and
PTCH1-1C [29].
Cyclin D2
To determine whether GLI1 regulates Cyclin D2 in
medulloblastomas, we quantified levels of Cyclin D2
transcript upon silencing of GLI1 by siRNA in the Daoy
medulloblastoma cell line. We observed a decrease in
Cyclin D2 expression in comparison to controls, which
suggests that GLI1 may up-regulate Cyclin D2, concur-
ring with previous reports showing similar results in
GLI1 transformed epithelial cells [13]. This evidence is
strengthened by the presence of the GLI1 consensus
binding sequence on the Cyclin D2 promoter [13]. To
complete this study, we determined the expression of
Cyclin D2 in 6 medulloblastoma cell lines and 14 tumor
samples, and overall, we observed high expression levels
of Cyclin D2 that correlated with high levels of GLI1
expression. These results indicate that Cyclin D2 may be
positively regulated by GLI1 in medulloblastomas.
GLI1 silencing in the astrocytic cell line U87MG led
to increased Cyclin D2 expression in comparison with
controls transfected with scrambled siRNA and untrans-
fected cells. Our results suggest that GLI1 does not up-
regulate Cyclin D2. These results do not concur with a
previous report showing up-regulation of Cyclin D2 in a
GLI1 transformed epithelial cell line [13]. This discre-
pancy suggests there may be two regulatory pathways:
first, the differential regulatory action of the Shh signal
(it may vary in different tissue types); and second, the
dual nature of Cyclin D2, behaving at times as an onco-
gene and other times as a tumor suppressor gene [33].
Cyclin D2 expression was either low or absent in 8
astrocytic cell lines in comparison with normal brain tis-
sue, although we detected expression of Cyclin D2 pro-
tein in all these cell lines, with the exception of
SW1044. However, even protein expression was very
low in comparison with the housekeeping gene GAPDH,
used as a positive internal control. We detected low
expression levels of Cyclin D2 transcript in U87MG,
A172, LN405, T98G and SW1088 cell lines, which may
correlate with low protein expression. Paradoxically, two
astrocytic cell lines (CCF-STTG-1 and GOS-3) did not
appear to express Cyclin D2 transcript, however, low
levels of protein expression was detected. This suggests
two possibilities: First, early degradation of Cyclin D2
mRNA due to a short half-life, and second, the possibi-
lity of differential splicing. We failed to detect expres-
sion of Cyclin D2 protein in any of the tumor samples.
Exploration of epigenetic regulation of Cyclin D2 in
medulloblastomas and astrocytomas was motivated by
previous studies which had revealed Cyclin D2 silencing
in cancers such as breast [34], lung [35], and prostate
[36], due to promoter hypermethylation.
Our study revealed, to a certain extent, hypermethyla-
tion of the Cyclin D2 promoter, although methylation
did not fully correlate with silencing of expression in
medulloblastoma cell lines. Interestingly, the methyla-
tion of the promoter in primary tumor samples was
associated with low or no expression of Cyclin D2.
We treated astrocytic cell lines that did not express
Cyclin D2 with the demethylating drug 5-Aza-2’-deoxy-
cytidine and the HDAC inhibitor TSA. The combination
of these two drugs improves epigenetic modulation [37].
After 72 h of treatment, we were able to observe Cyclin
D2 expression in these cell lines (p = 0.0014). Our
results are contrary to another study [38] that showed
high levels of Cyclin D2 expression in the astrocytic cell
lines, U87MG and T98G, and a decrease in Cyclin D2
expression after treatment with the HDAC inhibitor
SAHA. Our results suggest that the demethylating agent
rather than TSA, is responsible for Cyclin D2 re-expres-
sion. However, when we treated these two cell lines
with only 5-Aza-2’-deoxycytidine, we observed little to
no expression of Cyclin D2. However, after 5-Aza-2’-
deoxycytidine and TSA treatment, there was an increase
in expression of Cyclin D2 in T98G, but not in U87MG
cell line (accompanied by low expression levels of the
Cyclin D2 protein).
Despite hemi-methylation of the Cyclin D2 promoter
in U87MG cells, there was no change in Cyclin D2
expression after treatment. We assessed the hyper-
methylation status of the Cyclin D2 promoter in 8 cell
lines and 44 astrocytic tumors by studying two putative
CpG islands. SW1783 and CCF-STTG-1 cells appeared
to be methylated by MSP but not by MCA-Meth.
Neither MCA-Meth nor MSP detected methylation in
two other astrocytic cell lines (LN405 and SW1088).
Moreover, the A172 cell line did not show methylation
or even partial methylation at the two CpG sites in spite
of no Cyclin D2 expression in this cell line. Treatment
with 5-Aza-2’-deoxycytidine and TSA induced expres-
sion of Cyclin D2, indicating that a third CpG island
that we did not analyze may play an important role in
regulating Cyclin D2 expression in this cell line. Unfor-
tunately, we were unable to obtain any primers to assess
hypermethylation at this CpG region. Interestingly, a
GLI1 binding consensus sequence is also located at the
third CpG-rich region of Cyclin D2 promoter, indicating
the possibility of “patches hypermethylation” at this pro-
moter [39] (differential methylation pattern in a promo-
ter region which is supposed to be distributed at CpG
rich regions).
Plakloglobin
We attempted to determine Plakoglobin expression in
the Daoy medulloblastoma cell line upon GLI1 silencing.
Plakoglobin expression was decreased when compared
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with control-transfected and untransfected cell lines.
This indicates that GLI1 may positively regulate Plako-
globin expression. However, our results do not concur
with a previous report which suggests that GLI1 down-
regulates Plakoglobin in GLI1 transformed epithelial
cells [13]. Additionally, we assessed Plakoglobin expres-
sion in 6 medulloblastoma cell lines and 14 tumor sam-
ples. A majority of the cell lines and tumor samples
displayed high expression levels of Plakoglobin, while
only a few of the tumor samples showed little or no
expression of Plakoglobin. Notably, one report suggests
that high expression of Plakoglobin in medulloblastoma
samples is considered to be of high prognostic value
[40]. Therefore, our results may support high expression
and up-regulation of Plakoglobin by GLI1 in
medulloblastomas.
High levels of Plakoglobin expression after GLI1 silen-
cing in the U87MG astrocytoma cell line is not indica-
tive of positive regulation of this gene by GLI1. This
result concurs with a previous study on GLI1-trans-
formed epithelial cells [13]. We then sought to deter-
mine Plakoglobin expression in 8 astrocytic cell lines
and 23 primary astrocytic tumor samples. More than
60% (5/8) of the cell lines and 89% (24/27) of the tumor
samples expressed Plakoglobin at lower levels than nor-
mal adult brain tissue. Interestingly, there was a distinct
pattern of Plakoglobin expression amongst astrocytic
tumor samples: low-grade samples expressed Plakoglo-
bin, while a few high-grade samples also showed high
expression levels of Plakoglobin in absence of GLI1 tran-
script. However, the remaining samples all showed low
levels of Plakoglobin expression in presence of GLI1
transcript. These results support that GLI1 does not
appear to up-regulate Plakoglobin in astrocytomas.
PAX6
Silencing of GLI1 in Daoy cells indicated that GLI1 may
up-regulate the expression of the homeodomain tran-
scription factor I PAX6 in medulloblastomas. We also
determined the expression of PAX6 in 6 medulloblas-
toma cell lines and 14 primary tumor samples and
observed all cell lines with the exception of two
expressed high levels of PAX6. Similarly, a majority of
the primary tumor samples expressed high levels of
PAX6 transcript compared to normal brain tissue. Pre-
vious studies have shown that GLI1 down-regulates
PAX6 gene expression during normal neuronal develop-
ment [14,41,42]. PAX6 is a transcription factor which
regulates several genes involved in cell fate, proliferation,
as well as migration of neuroectodermal precursor cells
during development [43,44]. Interestingly, this suggests
different mechanisms of Shh regulation during normal
and malignant tissue development. A few studies report
high expression levels of PAX6 in medulloblastoma
samples [45]. Due to the multifunctional roles of this
group of genes, it is entirely possible that other mechan-
isms regulating PAX6 in medulloblastomas exist, which
further need to be explored.
Subsequent to GLI1 silencing, we observed an increase
in PAX6 expression in the transfected astrocytoma cell
line U87MG. A majority of the cell lines displayed low
levels of PAX6 despite high GLI1 expression, as was
similarly seen in primary astrocytic tumor samples.
Thus, GLI1 does not appear to up-regulate PAX6
expression in astrocytic tumors.
NKX2.2
GLI1 silencing suggests that GLI1 may up-regulate the
homeodomain transcription factor II NKX2.2. in medul-
loblastomas. We failed to detect expression of NKX2.2
transcript in 3 cell lines, observed low expression in 2,
and high expression in only one cell line. This pattern
of NKX2.2 transcript expression was recapitulated in
tumor samples, and was associated with high levels of
PAX6 transcript in cell lines and tumors.
GLI1 silencing did not perturb NKX2.2 expression in
the astrocytic cell line U87MG. A majority of astrocytic
cell lines (75%) and astrocytoma samples (70%) showed
either low or no expression of NKX2.2 compared to
normal adult brain tissue. Nevertheless, a few high-
grade samples expressed NKX2.2 at very high levels
when GLI1 was expressed at low levels. Overall, a
majority of the samples displayed low levels of NKX2.2
expression in the presence of high GLI1 expression.
Interestingly, however, reports suggest that Shh signal-
ing up-regulates NKX2.2 expression during normal neu-
ronal development [42,46]. Low expression levels of
NKX2.2 seen in our study, despite active Shh signaling,
is suggestive of differential Shh signaling during normal
development and in astrocytomas. Our study further
supports a previous report [47] which shows that
NKX2.2 is a direct target gene of Shh signaling, and is
up-regulated during normal development.
Statistical analysis
Statistical analysis by the Fisher’s test revealed signifi-
cant correlations of GLI1 expression with PAX6 (p =
0.015) and NKX2.2 (p = 0.015) expression in medullo-
blastoma cell lines. However, we did not find significant
correlations in the expression of GLI1 with PTCH1,
Cyclin D2 or Plakoglobin in the medulloblastoma cell
lines. Similarly, in medulloblastoma primary tumor sam-
ples, only expression of NKX2.2 showed significant cor-
relation with GLI1 expression (p = 0.004).
On the contrary, we observed significant correlation of
GLI1 expression with downstream target genes PTCH1
(p = 0.07), Cyclin D2 (p = 0.006), Plakoglobin (p = 0.02),
PAX6 (p = 0.006) and NKX.2.2 (p = 0.0001) in
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astrocytoma cell lines. Finally, GLI1 expression corre-
lated significantly with downstream target genes PTCH1
(p = 0.005), Cyclin D2 (p = 0.04), Plakoglobin (p =
0.006), PAX6 (p = 0.002) and NKX2.2 (p = 0.008) in
astrocytoma primary tumor samples.
Conclusions
We report that Cyclin D2 and PTCH1 are regulated by
two mechanisms: at the transcriptional level and at the
epigenetic level. GLI1 appears to up-regulate PTCH1
expression in both medulloblastomas and astrocytomas,
and remaining genes tested, namely, Cyclin D2, Plako-
globin, PAX6, and NKX2.2, only in medulloblastomas.
Analysis of promoter methylation suggests that epige-
netic regulation of Cyclin D2 is stronger in astrocytomas
than in medulloblastomas, while epigenetic regulation of
PTCH1 is weak in both tumors. Based on our results,
we advocate that molecules that inhibit Shh activation
as well as epigenetic modulator drugs may be effectively
used for the treatment of astrocytoma tumors.
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